Cargando…

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): prespecified analysis of the phase III ustekinumab trial in patients with SLE

OBJECTIVE: The Lupus Foundation of America Rapid Evaluation of Activity in Lupus (LFA-REAL) system is a novel and simple SLE disease activity instrument, consisting of a tandem clinician-reported (ClinRO) and patient-reported (PRO) outcome measure. The aim of this study was to compare the LFA-REAL s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Askanase, Anca D, Tang, Wei, Zuraw, Qing, Gordon, Robert, Brotherton, Betsy, Merrill, Joan T
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BMJ Publishing Group 2023
Materias:	Epidemiology and Outcomes
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10083883/ https://www.ncbi.nlm.nih.gov/pubmed/37012059 http://dx.doi.org/10.1136/lupus-2022-000875

Ejemplares similares

Evaluation of the LFA-REAL clinician-reported outcome (ClinRO) and patient-reported outcome (PRO): data from the Peruvian Almenara Lupus Cohort
por: Ugarte-Gil, Manuel Francisco, et al.
Publicado: (2020)

Development of Clinician-Reported Outcome (ClinRO) and Patient-Reported Outcome (PRO) Measures for Eyebrow, Eyelash and Nail Assessment in Alopecia Areata
por: Wyrwich, Kathleen W., et al.
Publicado: (2020)

Preliminary test of the LFA rapid evaluation of activity in lupus (LFA-REAL): an efficient outcome measure correlates with validated instruments
por: Askanase, Anca, et al.
Publicado: (2015)

Scoring systemic lupus erythematosus (SLE) disease activity with simple, rapid outcome measures
por: Thanou, Aikaterini, et al.
Publicado: (2019)

Protocol for virtual physical examination in an observational, longitudinal study evaluating virtual outcome measures in SLE
por: Askanase, Anca D, et al.
Publicado: (2023)

Which outcome measures in SLE clinical trials best reflect medical judgment?
por: Thanou, Aikaterini, et al.
Publicado: (2014)

Evaluation of SLE arthritis using frequency domain optical imaging
por: Marone, Alessandro, et al.
Publicado: (2021)

Generation of evidence supporting the content validity of SF-36, FACIT-F, and LupusQoL, and novel patient-reported symptom items for use in patients with systemic lupus erythematosus (SLE) and SLE with lupus nephritis (LN)
por: Williams-Hall, Rebecca, et al.
Publicado: (2022)

Development and content validity of the Lupus Foundation of America rapid evaluation of activity in lupus (LFA-REAL™): a patient-reported outcome measure for lupus disease activity
por: Askanase, Anca D., et al.
Publicado: (2019)

Gender differences in SLE: report from a cohort of 417 Caucasian patients
por: Trentin, Francesca, et al.
Publicado: (2023)

Cutaneous vasculitis in SLE
por: Kallas, Romy, et al.
Publicado: (2020)

SARS-CoV-2 vaccines in patients with SLE
por: Tang, Wei, et al.
Publicado: (2021)

Health information use by patients with systemic lupus erythematosus (SLE) pre and during the COVID-19 pandemic
por: Cardwell, Francesca S, et al.
Publicado: (2022)

Is frailty a relevant concept in SLE?
por: Katz, Patricia P, et al.
Publicado: (2017)

Associates and predictors of pleurisy or pericarditis in SLE
por: Ryu, Seungwon, et al.
Publicado: (2017)

Progression of subclinical and clinical cardiovascular disease in a UK SLE cohort: the role of classic and SLE-related factors
por: Haque, Sahena, et al.
Publicado: (2018)

2021 DORIS definition of remission in SLE: final recommendations from an international task force
por: van Vollenhoven, Ronald F, et al.
Publicado: (2021)

Independent association of glucocorticoids with damage accrual in SLE
por: Apostolopoulos, Diane, et al.
Publicado: (2016)

Predictors of incident proteinuria among patients with SLE
por: Duarte-García, Alí, et al.
Publicado: (2017)

Strong viral associations with SLE among Filipinos
por: Vista, Evan S, et al.
Publicado: (2017)

Patient perceptions and preferences of biologic therapies in SLE
por: Lim, S Sam, et al.
Publicado: (2019)

The association between diet and glucocorticoid treatment in patients with SLE
por: Lourdudoss, Cecilia, et al.
Publicado: (2016)

Herpes zoster in SLE: prevalence, incidence and risk factors
por: Kwan, Andrew, et al.
Publicado: (2022)

Rheumatologists’ perspective on hydroxychloroquine guidelines
por: Winebrake, James, et al.
Publicado: (2020)

Quantifying the burden of steroid-related damage in SLE in the Hopkins Lupus Cohort
por: Davidson, Julie E, et al.
Publicado: (2018)

Measuring cataract outcomes
por: Buchan, John
Publicado: (2022)

Presentation of SLE in UK primary care using the Clinical Practice Research Datalink
por: Nightingale, Alison L, et al.
Publicado: (2017)

Treatment Outcome of Metastatic Spine Tumor in Lung Cancer Patients: Did the Treatments Improve Their Outcomes?
por: Uei, Hiroshi, et al.
Publicado: (2017)

Exploring lifetime occupational exposure and SLE flare: a patient-focussed pilot study
por: Squance, Marline L, et al.
Publicado: (2014)

Disease activity patterns over time in patients with SLE: analysis of the Hopkins Lupus Cohort
por: Györi, Noémi, et al.
Publicado: (2017)

Disease duration, age at diagnosis and organ damage are important factors for cardiovascular disease in SLE
por: Nived, Ola, et al.
Publicado: (2020)

Development and validation of a simple lupus severity index using ACR criteria for classification of SLE
por: Bello, Ghalib A, et al.
Publicado: (2016)

Evaluating disease control following belimumab treatment in patients with SLE enrolled in the US OBSErve study
por: Hunnicutt, Jacob N, et al.
Publicado: (2022)

Clinicians approaches to management of background treatment in patients with SLE in clinical remission: results of an international observational survey
por: Ngamjanyaporn, Pintip, et al.
Publicado: (2017)

Tacrolimus in non-Asian patients with SLE: a real-life experience from three European centres
por: Tani, Chiara, et al.
Publicado: (2018)

Glucocorticoid discontinuation in patients with SLE with prior severe organ involvement: a single-center retrospective analysis
por: Nakai, Takehiro, et al.
Publicado: (2022)

Improving resource utilisation in SLE drug development through innovative trial design
por: Garces, Sandra, et al.
Publicado: (2023)

Intermittent and Persistent Type 2 lupus: patient perspectives on two distinct patterns of Type 2 SLE symptoms
por: Eudy, Amanda M, et al.
Publicado: (2022)

Assessing cognitive impairment in SLE: examining relationships between resting glucose metabolism and anti-NMDAR antibodies with navigational performance
por: Ploran, Elisabeth, et al.
Publicado: (2019)

Overcoming barriers to recruitment and retention of African–American women with SLE in behavioural interventions: lessons learnt from the WELL study
por: Drenkard, Cristina, et al.
Publicado: (2020)

Cannot write session to /tmp/vufind_sessions/sess_012k180viqtm1hor1kbkqp6ddo